Bohen Sean's Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Sep 22, 2022
- Accession no.
- 0001415889-22-009880
- Filed
- Sep 22, 2022
- Trade date
- Sep 21, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. It was filed 1 day after the trade.
This filing was later replaced by the amendment 0001415889-22-009915 (Sep 23, 2022). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bohen SeanCIK 0001831218 | Director, Officer (PRESIDENT AND CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 21, 2022 | Common Stock | AGrant or awardAcquired | +20,000 | –F1 | – | 74,279 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The weighted average purchase price for the transaction reported was $3.16, and the range of prices were between $3.15 and $3.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.